Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era
Significant strides have been made in the durability, portability, and safety of mechanical circulatory support devices (MCS). Although transplant is considered the standard treatment for advanced heart failure, limits in organ availability leave a much larger pool of recipients in need versus donor...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Cardiology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2012/524961 |
id |
doaj-089792cf53a748a0983cd7fab92fc2e6 |
---|---|
record_format |
Article |
spelling |
doaj-089792cf53a748a0983cd7fab92fc2e62020-11-24T22:08:32ZengHindawi LimitedCardiology Research and Practice2090-80162090-05972012-01-01201210.1155/2012/524961524961Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological EraKeith M. Swetz0John M. Stulak1Shannon M. Dunlay2Ellin F. Gafford3Division of General Internal Medicine, Department of Medicine, Section of Palliative Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Cardiovascular Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Cardiovascular Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USAPalliative Medicine, Ross Heart Hospital, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USASignificant strides have been made in the durability, portability, and safety of mechanical circulatory support devices (MCS). Although transplant is considered the standard treatment for advanced heart failure, limits in organ availability leave a much larger pool of recipients in need versus donors. MCS is used as bridge to transplantation and as destination therapy (DT) for patients who will have MCS as their final invasive therapy with transplant not being an option. Despite improvements in quality of life (QOL) and survival, defining the optimal candidate for DT may raise questions regarding the economics of this approach as well as ethical concerns regarding just distribution of goods and services. This paper highlights some of the key ethical issues related to justice and the costs of life-prolonging therapies with respect to resource allocations. Available literature, current debates, and future directions are discussed herein.http://dx.doi.org/10.1155/2012/524961 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Keith M. Swetz John M. Stulak Shannon M. Dunlay Ellin F. Gafford |
spellingShingle |
Keith M. Swetz John M. Stulak Shannon M. Dunlay Ellin F. Gafford Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era Cardiology Research and Practice |
author_facet |
Keith M. Swetz John M. Stulak Shannon M. Dunlay Ellin F. Gafford |
author_sort |
Keith M. Swetz |
title |
Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era |
title_short |
Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era |
title_full |
Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era |
title_fullStr |
Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era |
title_full_unstemmed |
Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era |
title_sort |
management of advanced heart failure in the elderly: ethics, economics, and resource allocation in the technological era |
publisher |
Hindawi Limited |
series |
Cardiology Research and Practice |
issn |
2090-8016 2090-0597 |
publishDate |
2012-01-01 |
description |
Significant strides have been made in the durability, portability, and safety of mechanical circulatory support devices (MCS). Although transplant is considered the standard treatment for advanced heart failure, limits in organ availability leave a much larger pool of recipients in need versus donors. MCS is used as bridge to transplantation and as destination therapy (DT) for patients who will have MCS as their final invasive therapy with transplant not being an option. Despite improvements in quality of life (QOL) and survival, defining the optimal candidate for DT may raise questions regarding the economics of this approach as well as ethical concerns regarding just distribution of goods and services. This paper highlights some of the key ethical issues related to justice and the costs of life-prolonging therapies with respect to resource allocations. Available literature, current debates, and future directions are discussed herein. |
url |
http://dx.doi.org/10.1155/2012/524961 |
work_keys_str_mv |
AT keithmswetz managementofadvancedheartfailureintheelderlyethicseconomicsandresourceallocationinthetechnologicalera AT johnmstulak managementofadvancedheartfailureintheelderlyethicseconomicsandresourceallocationinthetechnologicalera AT shannonmdunlay managementofadvancedheartfailureintheelderlyethicseconomicsandresourceallocationinthetechnologicalera AT ellinfgafford managementofadvancedheartfailureintheelderlyethicseconomicsandresourceallocationinthetechnologicalera |
_version_ |
1725816119705468928 |